Launch and market access
- If the decision is earlier
- Prepare the delivery pathway before the recommendation lands.
- If the decision is later
- Use the interval to resolve the binding gate rather than repeat the evidence review.
Part 3 of 4 Following a decision through the record
From published evidence to standard of care: why timing varies
Two positive trials can reach a guideline in similar time and reach patients years apart. The difference is the number and shape of the gates between them: whether the change substitutes a therapy or adds one, and whether the delivery pathway already exists. That is the clock a launch plan should use.
For launch leads and market access teams deciding when to build a delivery pathway.
01 Fast case
A fast case: an oral drug added to an existing pathway
An SGLT2 inhibitor was approved for heart failure with reduced ejection fraction about eight months after its pivotal trial was published. The European guideline gave the class a strong recommendation within two years; the American guideline followed within three. The drug was oral, familiar from diabetes practice, and added to a titration sequence that already existed.
The gate that opened was a recommendation. The implementation cost was a prescription.
| Date | Body | Act | Population | State |
|---|---|---|---|---|
| Trial sponsors | Pivotal trial published Trial paper | Heart failure with reduced ejection fraction | Open | |
| FDA | Indication approved Label | Heart failure with reduced ejection fraction | Open | |
| ESC | Guideline recommendation Guideline | Heart failure with reduced ejection fraction, Class I | Open | |
| AHA/ACC/HFSA | Guideline recommendation Guideline | Heart failure with reduced ejection fraction, Class 1 | Open |
The interval that matters is between the trial paper and the guideline, not between the approval and the launch.
02 Slow case
A slow case: an injectable that creates a new pathway
The PCSK9 inhibitor class reached a guideline recommendation about three years after the first approval. The recommendation was the easy gate. The harder ones were a prior-authorization regime, a list price near fourteen thousand dollars a year, and a specialist referral pathway many primary care systems did not have.
The class was recommended and under-prescribed at the same time, for years. A guideline placement is not a practice change.
| Date | Body | Act | Population | State |
|---|---|---|---|---|
| FDA | First class approvals Labels | Heterozygous familial hypercholesterolaemia and established atherosclerotic disease | Open | |
| Trial sponsors | Outcomes trial published Trial paper | Stable atherosclerotic disease | Open | |
| Trial sponsors | Second outcomes trial published Trial paper | Recent acute coronary syndrome | Open | |
| AHA/ACC | Cholesterol guideline Guideline | Very high-risk atherosclerotic disease | Open | |
| Payers | Prior-authorization regime Plan policy | A subset of the label population | Pending |
The guideline opened. The prior-authorization and referral gates did not open on the same clock.
03 The shape
The shape of the change sets the clock
Both cases had positive outcome trials and strong recommendations. What separated them was substitution versus addition, an existing pathway versus a new one, and a budget-neutral line item versus a budget event.
- Does the recommendation substitute a therapy or add one?
- Does the delivery pathway already exist at the sites that would use it?
- Is the price a line item or a budget event?
- Which gate is binding?
Our reading Timing follows the number and shape of the gates more than the strength of the evidence. The comparison illustrates the point. A guideline placement and a practice change are different events.
Who needs to prepare if the date moves?
What each team changes if the decision comes earlier or later than planned.
HEOR
- If the decision is earlier
- Frame the budget question for the population the guideline will name.
- If the decision is later
- Reassess the price and monitoring burden against the actual covered population.
Business development
- If the decision is earlier
- Separate a guideline event from a practice-change event in the valuation.
- If the decision is later
- Keep the gate that is still closed visible in the transaction assessment.
Dates, acts and populations come from the named document; a study's population is the one it enrolled. A body's account of its own rule is a record of the account, consensus is a dated summary rather than a source, and "Our reading" marks interpretation, not a finding.
Bring the action and your deadline
Which decision matters to your team, and by what date? Include the population and the plan it would inform.
Ask about this guide